Get started
Author

QiaoLi Lv

Observed names: Lv, Qiaoli, Qiaoli Lv
ORCID: 0000-0002-0452-7032
Observed ORCID: 0000-0002-0452-7032
OpenAlex ID: A5112495189
NAT10 and ac4C modification in cancer immunity and metabolism: emerging mechanisms and therapeutic potential
2026 · Yanqi Yang, Changren Chen, et al. · Journal of Translational Medicine · 6
Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib
2026 · Mengting Yu, Yanyun Hong, et al. · Journal of Experimental & Clinical Cancer Research · 6
ATR inhibitors: from targeting the DNA damage response to exploiting synthetic lethality—A paradigm shift in Cancer therapy
2026 · Xin Zhou, Qi Qin, et al. · Bioorganic Chemistry · 4
Synthesis and 4D-QSAR Studies of Alanine Hydroxamic Acid Derivatives as Aminopeptidase N Inhibitors
2019 · Min Gao, QiaoLi Lv, et al. · Medicinal Chemistry · 4
Advances in Platinum(IV) Functional Axial Ligand Research: A Prospective Perspective
2026 · Zhenjie Cheng, Mei Zhu, et al. · Archiv der Pharmazie · 3
MOV10, a novel immunotherapy and prognostic biomarker, contributes to glioma development by regulating autophagy
2026 · Feiyu Wang, Linlin Ruan, et al. · Scientific Reports · 1
PDF
Immunohistochemical biomarker-associated radiomics for classifying thymic epithelial tumors: a multicenter retrospective study
2026 · Yutian Zhang, Yangzhong Guo, et al. · npj Precision Oncology · 1
PDF
Role of glycosylated small noncoding RNAs in tumor: mechanism, function and clinical significance
2026 · Yanan Feng, Zhangren Chen, et al. · Glycoconjugate Journal
A two-stage genome-wide association study to identify germline polymorphisms associated with survival of nasopharyngeal carcinoma
2026 · Tong Li, LuLu Yu, et al. · Pathology - Research and Practice
RBM43 promotes glioma aggressiveness and shapes the immune microenvironment through macrophage polarization
2026 · ZiLong Tan, DaPeng Wang, et al. · Discover Oncology
METTL3 stabilizes FASN mRNA by mediating m6A modification to promote malignant progression of diffuse large B-cell lymphoma
2026 · Xiangxiang Song, Yun Zhong, et al. · Cell & Bioscience
Additional file 1 of Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib
2026 · Yu, Mengting, Hong, Yanyun, et al. · Figshare
Works count: 12
Citation count: 24
H-index: 3
I10-index:
Year
Topic
Type